Integrated Wealth Concepts LLC lowered its position in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) b

Corient Private Wealth LP increased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:

Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Confere

Engineers Gate Manager LP raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBI

Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-W

Amundi lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 8.3% during the

Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conf

Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transc

RBC Capital analyst Brian Abrahams reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Outperf

Continuum Advisory LLC decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBI

Citigroup analyst Yigal Nochomovitz maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and

SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced

NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leavin

NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovere

Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

B. Metzler seel. Sohn and Co. AG acquired a new stake in shares of Neurocrine Biosciences, Inc. (NAS

Allworth Financial LP purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NB

Neurocrine Biosciences is rated a 'Buy' based on robust cash flows, strong product launches, and a d

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

NBIX's Ingrezza sales climb 17% in 1H 2026 as strong volume drives a higher full-year outlook, but p

Neurocrine's Q2 beat and higher Ingrezza guidance highlight strong growth, but rising spending and e

Neurocrine pairs rapid growth and expanding rare-disease assets with a premium sales valuation, maki

BlackRock Inc. purchased a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) during

Jim Cramer recommended buying Uber, Tanger, Rockwell Automation, Amcor, and Neurocrine Biosciences.

Neurocrine's shares fell 12% in a month as Vykat XR safety concerns mount, but Ingrezza and Crenessi

ABN AMRO Bank N.V. bought a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) du

Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-W

Reports of serious adverse events and deaths linked to Neurocrine's VYKAT XR for Prader-Willi sy

INGREZZA is the only vesicular monoamine transporter 2 inhibitor with clinical trial data demonstrat

Tom Lee's GRNJ added First Solar, Zoom and eight other stocks in its latest rebalance as assets

Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, includi

Neurocrine (NBIX) to acquire Soleno Therapeutics (SLNO) for $2.9B to expand its rare disease portfol

Neurocrine's Phase 2 trial of NBI-1070770 in major depressive disorder missed its main goal but

A powerful surge in AI-related stocks — led by a 9% advance in NVIDIA Corp. (NASDAQ:NVDA) over the p

Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session.

Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER

Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quart

Companies Reporting Before The Bell • BBVA (NYSE:BBVA) is likely to report earnings for its third q